Table 3.
Predictive power of maternal serum CYFRA 21–1 levels in symptomatic women with preeclampsia (PE_state) and in asymptomatic women who later developed preeclampsia (PE_long)
| Predictor | AUC | 95 % CI | Cut-off (ng/ml) | Sensitivity | Specificity | p-value |
|---|---|---|---|---|---|---|
| For existing Preeclampsia (PE_state) | ||||||
| CYFRA 21–1 level at visit: | ||||||
| 4 | 0.85 | 0.68–1 | 3.6 | 0.67 | 0.96 | <0.001 |
| 5 | 0.92 | 0.85–1 | 3.1 | 0.92 | 0.8 | <0.001 |
| 6 | 0.88 | 0.8–0.97 | 3.9 | 0.89 | 0.77 | <0.001 |
| For subsequent Preeclampsia (PE_long) | ||||||
| CYFRA 21–1 level at visit: | ||||||
| 1 | 0.28 | 0.02–0.53 | NDa | ND | ND | 0.088 |
| 2 | 0.51 | 0.29–0.74 | 2.5 | 0.44 | 0.7 | 0.909 |
| 3 | 0.54 | 0.3–0.77 | 2.8 | 0.22 | 0.9 | 0.785 |
| 4 | 0.71 | 0.51–0.9 | 2.1 | 0.88 | 0.53 | 0.037 |
| 5 | 0.70 | 0.55–0.86 | 2.4 | 1 | 0.51 | 0.012 |
| 6 | 0.69 | 0.48–0.9 | 2.7 | 1 | 0.34 | 0.074 |
| CYFRA 21–1 increase between visits: | ||||||
| 1 and 2 | 0.46 | 0.24–0.68 | ND | ND | ND | 0.724 |
| 2 and 3 | 0.48 | 0.25–0.71 | ND | ND | ND | 0.857 |
| 3 and 4 | 0.61 | 0.41–0.81 | 0.6 | 0.67 | 0.94 | 0.287 |
| 4 and 5 | 0.66 | 0.51–0.82 | 0.6 | 0.83 | 0.76 | 0.042 |
| 5 and 6 | 0.69 | 0.48–0.9 | 2.0 | 0.67 | 0.85 | 0.074 |
aCut-off values, sensitivity, and specificity are not provided if the AUC is <0.5
AUC area under the curve, 95 % CI 95 % confidence interval, CYFRA 21–1 Cytokeratin fragment 21–1, PE preeclampsia